Global Markets Direct’s, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H2 2015′, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Overview 9
Therapeutics Development 10
Pipeline Products for Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Overview 10
Pipeline Products for Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 11
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 12
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 18
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 21
Advaxis, Inc. 21
Amgen Inc. 22
AstraZeneca Plc 23
AVEO Pharmaceuticals, Inc. 24
Critical Outcome Technologies Inc. 25
Daiichi Sankyo Company, Limited 26
Genentech, Inc. 27
Glycotope GmbH 28
Immunovative Therapies, Ltd. 29
Laboratoires Pierre Fabre SA 30
Mabion SA 31
MedImmune, LLC 32
Merck & Co., Inc. 33
Novartis AG 34
Oncolytics Biotech Inc. 35
Ono Pharmaceutical Co., Ltd. 36
Panacea Biotec Limited 37
PCI Biotech AS 38
Shionogi & Co., Ltd. 39
Symphogen A/S 40
Threshold Pharmaceuticals, Inc. 41
VentiRx Pharmaceuticals, Inc. 42
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
AdIL-24 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AlloVax - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
alpelisib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
axalimogene filolisbac - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AZD-5069 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AZD-9150 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
bleomycin sulfate - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
cetuximab biobetter - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
cetuximab biosimilar - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
cetuximab biosimilar - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
cetuximab biosimilar - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
COTI-2 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
duligotuzumab - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
durvalumab - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
durvalumab + tremelimumab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
elgemtumab - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ficlatuzumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
futuximab - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
motolimod - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
nivolumab - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
panitumumab - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
patritumab - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
pelareorep - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
pembrolizumab - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
S-488210 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
SB-01 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
tarloxotinib bromide - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
vinflunine ditartrate - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 126
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 194
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 195
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 196
Featured News & Press Releases 196
Aug 27, 2015: Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin 196
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 198
Disclaimer 199

List of Tables

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2015 10
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Development by Companies, H2 2015 (Contd...1) 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd...1) 19
Products under Development by Companies, H2 2015 (Contd...2) 20
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H2 2015 21
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2015 22
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H2 2015 23
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 24
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H2 2015 25
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 26
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech, Inc., H2 2015 27
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2015 28
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2015 29
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H2 2015 30
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H2 2015 31
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2015 32
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015 33
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2015 34
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2015 35
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 36
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015 37
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2015 38
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2015 39
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H2 2015 40
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 41
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015 42
Assessment by Monotherapy Products, H2 2015 43
Assessment by Combination Products, H2 2015 44
Number of Products by Stage and Target, H2 2015 46
Number of Products by Stage and Mechanism of Action, H2 2015 48
Number of Products by Stage and Route of Administration, H2 2015 50
Number of Products by Stage and Molecule Type, H2 2015 52
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015 126
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2015 194
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2015 195

List of Figures

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2015 10
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 16
Assessment by Monotherapy Products, H2 2015 43
Number of Products by Top 10 Targets, H2 2015 45
Number of Products by Stage and Top 10 Targets, H2 2015 45
Number of Products by Top 10 Mechanism of Actions, H2 2015 47
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 47
Number of Products by Routes of Administration, H2 2015 49
Number of Products by Stage and Routes of Administration, H2 2015 49
Number of Products by Molecule Types, H2 2015 51
Number of Products by Stage and Molecule Types, H2 2015 51